DELINIA INC has a total of 82 patent applications. It decreased the IP activity by 87.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are VECT HORUS, SMITH JEFFREY T L and BIOTEMPT BV.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 16 | |
#2 | EPO (European Patent Office) | 7 | |
#3 | Australia | 6 | |
#4 | WIPO (World Intellectual Property Organization) | 6 | |
#5 | Canada | 5 | |
#6 | China | 5 | |
#7 | Republic of Korea | 5 | |
#8 | Mexico | 5 | |
#9 | Singapore | 5 | |
#10 | Hungary | 3 | |
#11 | Israel | 3 | |
#12 | South Africa | 3 | |
#13 | Brazil | 2 | |
#14 | Chile | 2 | |
#15 | Colombia | 2 | |
#16 | Japan | 2 | |
#17 | EAPO (Eurasian Patent Organization) | 1 | |
#18 | Ecuador | 1 | |
#19 | United Kingdom | 1 | |
#20 | Hong Kong | 1 | |
#21 | Serbia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Analysing materials | |
#5 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Greve Jeffrey | 67 |
#2 | Jeffrey Greve | 12 |
#3 | Nagarajan Niranjana | 9 |
#4 | Kim Jungmin | 9 |
#5 | Cho John | 8 |
#6 | John Cho | 2 |
#7 | Niranjana Nagarajan | 2 |
#8 | Jungmin Kim | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020092554A1 | Multivalent regulatory t cell modulators | |
MX2019007002A | Multivalent regulatory t cell modulators. | |
KR20190083656A | IL-2 variants for the treatment of autoimmune diseases | |
US2017204154A1 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
EP3180020A1 | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
CA2954847A1 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |